DNA Electronics
DNAe said its semiconductor-based platform has potential to detect a broader variety of pathogens and resistance genes than current molecular technologies.
DNAe Receives $10.9M From BARDA for Near-Patient NGS Prototype
The award comes after DNAe completed the first phase of a contract valued at up to $51.9 million, which BARDA initiated in September 2016.
DNAe Boasts Low Levels of Pathogen Detection for Forthcoming Sepsis, Antibiotic Resistance Test
Premium
The firm said that its platform successfully detected pathogens and resistance markers at limits of detection as low as 1 CFU/ml in spiked blood samples.
As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
BARDA Awards $51.9M to DNAe to Develop Rapid Diagnostics
Under the contract, DNAe will develop tests for antimicrobial resistant infections and influenza that it submits to the FDA for clearance.